DE69034143D1 - Zusammensetzung, welche 5-Methyl-1-phenyl-2-(1 H)-pyridone enthält, zur fixierung und Vermeidung von fibrotischen Schädigungen - Google Patents

Zusammensetzung, welche 5-Methyl-1-phenyl-2-(1 H)-pyridone enthält, zur fixierung und Vermeidung von fibrotischen Schädigungen

Info

Publication number
DE69034143D1
DE69034143D1 DE69034143T DE69034143T DE69034143D1 DE 69034143 D1 DE69034143 D1 DE 69034143D1 DE 69034143 T DE69034143 T DE 69034143T DE 69034143 T DE69034143 T DE 69034143T DE 69034143 D1 DE69034143 D1 DE 69034143D1
Authority
DE
Germany
Prior art keywords
pyridone
methyl
phenyl
avoidance
fixation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69034143T
Other languages
English (en)
Other versions
DE69034143T2 (de
Inventor
Solomon B Margolin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69034143D1 publication Critical patent/DE69034143D1/de
Application granted granted Critical
Publication of DE69034143T2 publication Critical patent/DE69034143T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69034143T 1989-02-15 1990-02-15 Zusammensetzung, welche 5-Methyl-1-phenyl-2-(1 H)-pyridone enthält, zur fixierung und Vermeidung von fibrotischen Schädigungen Expired - Lifetime DE69034143T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1035436A JPH02215719A (ja) 1989-02-15 1989-02-15 線維化病変組織の修復並びに線維化病変の阻止剤
JP3543689 1989-02-15

Publications (2)

Publication Number Publication Date
DE69034143D1 true DE69034143D1 (de) 2004-07-08
DE69034143T2 DE69034143T2 (de) 2005-06-30

Family

ID=12441800

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69033863T Expired - Lifetime DE69033863T2 (de) 1989-02-15 1990-02-15 Verwendung von 5-methyl-1-phenyl-2-(1H)-pyridon zur Vorbeugung fibrotischer Schädigungen
DE69034143T Expired - Lifetime DE69034143T2 (de) 1989-02-15 1990-02-15 Zusammensetzung, welche 5-Methyl-1-phenyl-2-(1 H)-pyridone enthält, zur fixierung und Vermeidung von fibrotischen Schädigungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69033863T Expired - Lifetime DE69033863T2 (de) 1989-02-15 1990-02-15 Verwendung von 5-methyl-1-phenyl-2-(1H)-pyridon zur Vorbeugung fibrotischer Schädigungen

Country Status (9)

Country Link
EP (3) EP0458861B1 (de)
JP (1) JPH02215719A (de)
AT (1) ATE136215T1 (de)
AU (1) AU633541B2 (de)
CA (1) CA2010017C (de)
DE (2) DE69033863T2 (de)
DK (1) DK0458861T3 (de)
ES (2) ES2220612T3 (de)
WO (1) WO1990009176A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
BR9406461A (pt) * 1993-05-07 1996-01-30 Solomon Begelfor Margolin Composições e métodos para a reparação e prevenção de les~es fibróticas
EP0813409B1 (de) * 1995-03-03 2004-05-06 MARGOLIN, Solomon B. Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
EP1113798B1 (de) 1998-09-18 2003-01-02 Mepha AG Topisch verabreichbare alkyl-, phenyl-pyridone-arzneimittel
WO2002060446A1 (en) 2001-01-29 2002-08-08 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
JP4542743B2 (ja) 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
TW200418516A (en) * 2003-02-21 2004-10-01 Shionogi & Co Droplet dispersed ointment
WO2004073713A1 (ja) * 2003-02-21 2004-09-02 Shionogi & Co., Ltd. ピルフェニドンのゲル剤
CA2545813C (en) 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
CN1846699A (zh) 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CA2656017C (en) 2006-06-15 2014-02-04 Shanghai Genomics, Inc. Use of pyridone derivatives in the prevention and treatment of radiation-induced lung injuries
MX2007006347A (es) * 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma.
DK2170828T3 (da) 2007-06-20 2013-03-04 Auspex Pharmaceuticals Inc Substituerede n-aryl pyridinoner som fibrotiske inhibitorer
CN101918364B (zh) * 2008-10-21 2013-02-13 史跃年 用于治疗高蛋白尿的药物组合物
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8084475B2 (en) * 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
BR112013022766A2 (pt) 2011-03-08 2016-12-06 Auspex Pharmaceuticals Inc método de administração de d-pirfenidona e kit
CN103917223B (zh) * 2011-09-14 2017-08-08 盐野义制药株式会社 供吸入的药用组合物
EP2875001B1 (de) 2012-07-18 2019-01-09 Sunshine Lake Pharma Co., Ltd. Heterocyclische stickstoffderivate und deren anwendung in arzneimitteln
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AU2014366049B2 (en) 2013-12-19 2018-04-05 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
EP3307714A1 (de) 2015-01-26 2018-04-18 Ulkar Kimya Sanayii Ve Ticaret A. S. Verbessertes verfahren für die synthese und reinigung von pirfenidon
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
CN109223723B (zh) * 2017-07-11 2021-08-27 南京华威医药科技集团有限公司 吡非尼酮片剂及其制备方法和用途
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
MX2020005775A (es) * 2020-07-13 2022-01-14 Centro De Retina Medica Y Quirurgica S C Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6816241A (de) * 1967-12-01 1969-06-03
US3721676A (en) * 1969-11-12 1973-03-20 Merck & Co Inc Certain 3-amino-2(1h)pyridones
US3644626A (en) * 1969-11-25 1972-02-22 Merck & Co Inc Novel pyridones in compositions and methods for treating inflammation pain and fever
US3655897A (en) * 1971-01-25 1972-04-11 Merck & Co Inc Anti-inflammatory agents
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
ZA757570B (en) * 1974-12-09 1977-07-27 Affiliated Med Res A useful n-substituted pyridone
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤

Also Published As

Publication number Publication date
CA2010017A1 (en) 1990-08-15
EP1138329A3 (de) 2002-04-17
AU633541B2 (en) 1993-02-04
DK0458861T3 (da) 1996-08-12
JPH02215719A (ja) 1990-08-28
JPH0552814B2 (de) 1993-08-06
EP0458861A1 (de) 1991-12-04
ES2163389T3 (es) 2002-02-01
DE69033863D1 (de) 2002-01-03
DE69033863T2 (de) 2002-06-13
EP1138329B8 (de) 2006-05-17
EP0458861A4 (en) 1992-07-08
ES2220612T3 (es) 2004-12-16
CA2010017C (en) 1995-09-05
WO1990009176A1 (en) 1990-08-23
EP1138329B1 (de) 2004-06-02
EP0383591A2 (de) 1990-08-22
EP1138329A2 (de) 2001-10-04
EP0383591A3 (de) 1992-01-15
EP0383591B1 (de) 2001-11-21
ATE136215T1 (de) 1996-04-15
EP0458861B1 (de) 1996-04-03
AU4981290A (en) 1990-08-23
DE69034143T2 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
DE69034143D1 (de) Zusammensetzung, welche 5-Methyl-1-phenyl-2-(1 H)-pyridone enthält, zur fixierung und Vermeidung von fibrotischen Schädigungen
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
NZ227680A (en) Quinoline and naphthyridine derivatives, intermediates and pharmaceutical compositions
DE69118526D1 (de) Mittel zur transdermalen penetration von arzneimitteln
ES2095380T3 (es) Derivados de indano-2-carboxialquilo sustituidos en la posicion 2 utiles como inhibidores de la encefalinasa y la eca.
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
EP0471756A4 (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
DE3769495D1 (de) 2-(substituierte-imino)-6-aryl-3,6-dihydro-4-substituierte-1,5(2h)-pyrimidincarboxylsaeuren und analoga.
ES8800160A1 (es) Procedimiento de obtencion de acidos quinolincarboxilicos con propiedades antibacteriales.
EP0254951A3 (en) Novel 5(and/or 6)substituted 2-(2-imidazolin-2-yl)nicotinic acids, esters and salts, useful as herbicidal agents and novel intermediates for the preparation of said nicotinic acids, esters and salts
DE3888012D1 (de) Substituierte 4-[1H-Imidazol-1-yl]benzamide als antiarrhythmische Mittel.
IL104751A0 (en) Novel 5(and/or 6)substituted 2-(2-imidazolin-2-yl)nicotinic acids,esters and salts,useful as herbicidal agents and novel intermediates for the preparation of said nicotinic acis,esters and salts
MY104006A (en) 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases.
NO893256D0 (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
ZA871635B (en) 2-((2-pyridyl)methylsulfinyl)thienoimidazoles and related compounds as antiulcer agents
IT8621784A0 (it) Derivati ammidici eterociclici di acidi benzoici sostituiti e composizione terapeutiche che licontengono come principi attivi.
ATE89732T1 (de) Bakterientoetende gemische.
IT1199960B (it) Agenti stimolanti la crescita dei capelli e loro impiego
ATA63587A (de) Mittel zur erdalkaliduengung von gehoelzen
NO881798D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
DE3672196D1 (de) Formulierung auf basis von gelatine und glyzine zur behandlung der trockenheit der haut.
IT1179277B (it) Procedimento per la realizzazione dei bordi di antine o pianali per mobili e antine cosi' ottenute

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MARGOLIN, SOLOMON B., DALLAS, TEX., US

Owner name: KDL GMBH, ZUG, CH

8327 Change in the person/name/address of the patent owner

Owner name: INTERMUNE, INC., BRISBANE, CALIF., US